JP2024513692A5 - - Google Patents
Info
- Publication number
- JP2024513692A5 JP2024513692A5 JP2023555769A JP2023555769A JP2024513692A5 JP 2024513692 A5 JP2024513692 A5 JP 2024513692A5 JP 2023555769 A JP2023555769 A JP 2023555769A JP 2023555769 A JP2023555769 A JP 2023555769A JP 2024513692 A5 JP2024513692 A5 JP 2024513692A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/080142 | 2021-03-11 | ||
| CN2021080142 | 2021-03-11 | ||
| CNPCT/CN2022/076516 | 2022-02-16 | ||
| CN2022076516 | 2022-02-16 | ||
| PCT/CN2022/080297 WO2022188856A1 (en) | 2021-03-11 | 2022-03-11 | Method of treating diseases using gremlin1 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024513692A JP2024513692A (ja) | 2024-03-27 |
| JP2024513692A5 true JP2024513692A5 (https=) | 2025-03-19 |
| JPWO2022188856A5 JPWO2022188856A5 (https=) | 2025-03-19 |
Family
ID=83226314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555769A Pending JP2024513692A (ja) | 2021-03-11 | 2022-03-11 | グレムリン１アンタゴニストを使用して疾患を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240190950A1 (https=) |
| EP (1) | EP4304646A4 (https=) |
| JP (1) | JP2024513692A (https=) |
| KR (1) | KR20230156936A (https=) |
| CN (1) | CN116940380A (https=) |
| AU (1) | AU2022233762A1 (https=) |
| BR (1) | BR112023018204A2 (https=) |
| CA (1) | CA3213121A1 (https=) |
| MX (1) | MX2023010594A (https=) |
| TW (1) | TW202300527A (https=) |
| WO (1) | WO2022188856A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024504124A (ja) * | 2021-01-18 | 2024-01-30 | スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド | 新規の抗グレムリン１抗体 |
| WO2024213066A1 (en) * | 2023-04-13 | 2024-10-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Combination therapies involving grem1 antagonists for treatment of cancer |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
| CN119746060B (zh) * | 2025-03-07 | 2025-09-16 | 南昌大学第一附属医院 | 一种树突状细胞疫苗制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6339063B2 (ja) * | 2012-03-15 | 2018-06-06 | エスエヌユー アールアンドディービー ファウンデーション | グレムリン−１に対する抗体 |
| ES2898620T3 (es) * | 2013-03-14 | 2022-03-08 | Regeneron Pharma | Anticuerpos humanos contra GREM 1 |
| US10844051B2 (en) * | 2015-07-22 | 2020-11-24 | The Royal Institution For The Advancement Of Learning/Mcgill University | Substituted oxazoles for the treatment of cancer |
| GB201621635D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| PL3806898T3 (pl) * | 2018-06-18 | 2026-02-23 | UCB Biopharma SRL | Antagonista gremlin-1 do zastosowania w leczeniu nowotworu |
| JP2024504124A (ja) * | 2021-01-18 | 2024-01-30 | スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド | 新規の抗グレムリン１抗体 |
-
2022
- 2022-03-11 BR BR112023018204A patent/BR112023018204A2/pt unknown
- 2022-03-11 MX MX2023010594A patent/MX2023010594A/es unknown
- 2022-03-11 CN CN202280020454.8A patent/CN116940380A/zh active Pending
- 2022-03-11 KR KR1020237034659A patent/KR20230156936A/ko active Pending
- 2022-03-11 WO PCT/CN2022/080297 patent/WO2022188856A1/en not_active Ceased
- 2022-03-11 EP EP22766378.8A patent/EP4304646A4/en active Pending
- 2022-03-11 TW TW111109016A patent/TW202300527A/zh unknown
- 2022-03-11 JP JP2023555769A patent/JP2024513692A/ja active Pending
- 2022-03-11 CA CA3213121A patent/CA3213121A1/en active Pending
- 2022-03-11 AU AU2022233762A patent/AU2022233762A1/en active Pending
- 2022-03-11 US US18/549,928 patent/US20240190950A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024504124A5 (https=) | ||
| JP2024513692A5 (https=) | ||
| CL2026000193A1 (es) | Proceso de condensación de vapor a baja temperatura para usarse con captura de carbono. | |
| CL2025003847A1 (es) | Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano. | |
| CN307049005S (https=) | ||
| CN307048653S (https=) | ||
| CN307049732S (https=) | ||
| CN307048978S (https=) | ||
| CN307048529S (https=) | ||
| CN307048186S (https=) | ||
| CN307047919S (https=) | ||
| CN307047673S (https=) | ||
| CN307046249S (https=) | ||
| CN307046085S (https=) | ||
| CN307045981S (https=) | ||
| CN307045643S (https=) | ||
| CN307045445S (https=) | ||
| CN307045285S (https=) | ||
| CN307044842S (https=) | ||
| CN307044755S (https=) | ||
| CN307044716S (https=) | ||
| CN307044707S (https=) | ||
| BY24015C1 (https=) | ||
| BY24005C1 (https=) | ||
| BY23963C1 (https=) |